BTL is rolling out EXOMIND, a non-invasive brain stimulation treatment designed to improve mental and emotional well-being and Emface Eyes, a new periorbital rejuvenation applicator.
Both products were launched at the IMCAS World Congress 2025 in Paris, France.
EXOMIND is U.S. Food and Drug Administration-cleared for depression and is also approved by Health Canada and CE-marked for treating depression, anxiety symptoms, obsessive-compulsive disorder, and excessive eating disorders.
“The majority of my patients are on some form of antidepressant medication. With EXOMIND, we now offer an alternative that enhances patient well-being and provides them with the freedom to manage their mental wellness without relying solely on medication,” says New York City Facial Plastic Surgeon Yael Halaas, MD, in a news release.
EMFACE eyes is the newest applicator to the EMFACE platform. EMFACE employs synchronized radiofrequency technology to heat the dermis, stimulating collagen and elastin production. Concurrently, the high-intensity focused electrical stimulation (HIFES) selectively contracts facial muscles.
